TNF inhibitor
Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study.
... alternative TNF inhibitor group, the most frequent AEs were urinary tract infections ...alternative TNF inhibitor groups, respectively, and most commonly occurred within the musculoskeletal ...
8
Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples
... Introduction: Gene expression profiling is rapidly becoming a useful and informative tool in a much needed area of research. Identifying patients as to whether they will respond or not to a given treatment before ...
7
Factors that influence fatigue status in patients with severe rheumatoid arthritis (RA) and good disease outcome following 6 months of TNF inhibitor therapy: a comparative analysis
... The overarching aim of this study was to contribute to the rational development of appropriate prevention and management strategies for fatigue. This is contingent on iden- tifying its drivers. Reasons for minimal ...
9
Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review
... TNF inhibitor. Evidence for the efficacy of switching to a second anti-TNF agent after failing to respond to an initial one most often relies on open, uncontrolled and nonrandomized studies, whereas ...
12
The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug
... Background: Rheumatoid Arthritis (RA) is one of the most common autoimmune diseases, affecting approximately 1% of the UK adult population. Patients suffer considerable pain, stiffness and swelling and can sustain ...
15
Mental health, fatigue and function are associated with increased risk of disease flare following TNF inhibitor tapering in patients with rheumatoid arthritis: an exploratory analysis of data from the Optimizing TNF Tapering in RA (OPTTIRA) trial
... Baseline depression, measured by SF-36 mental health scale and DAS28, independently predict flare events in patients with sustained LDA who taper their anti-TNF agents. In addition to baseline depression, a range ...
8
Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort
... The results were very similar in patients with a clinical diagnosis of axSpA made by their treating rheumatolo- gist and those fulfilling the ASAS classification criteria for axSpA. The presentation of patients with ...
8
<p>Switch Rates and Total Cost of Care Associated with Apremilast and Biologic Therapies in Biologic-Naive Patients with Plaque Psoriasis</p>
... Because of its chronic disease course, psoriasis is asso- ciated with high direct medical costs that increase with severity. 8 Switching between treatments is common and has been seen in real-world studies. 9,10 The most ...
9
Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany
... the TNF inhibitor continuing ...one TNF inhibi- tor prescription during the baseline period and at least one claim in the follow-up ...their TNF inhibitor therapy before the baseline ...
11
Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain
... each TNF inhibitor and Markov modelling, in which patients who achieved ACR50 criteria continued to receive combination therapy but those who did not switched to ...cost-effective TNF ...
13
A multicentre, randomised, controlled, open label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission
... with TNF blockers, once started as therapy for RA, is usually con- tinued inde fi ...discontinue TNF inhibitor therapy while remaining in ...of TNF inhibitors may be feasible not only in ...
8
Health outcomes and unmet needs in patients with long-standing rheumatoid arthritis attending tertiary care in Greece: a cohort study
... Treatment with the first TNF inhibitor in rheumatoid arthritis patients in the Hellenic registry of biologic therapies improves quality of life especially in young patients with better b[r] ...
10
TNF-α- and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism
... that TNF- a markedly increased the ceramide content of L6 myotubes, consistent with a role for this sphingolipid mediator in the atrophic ...under TNF-a stimulation, the C18:0 species was found to be one of ...
19
Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor α inhibitors
... primarily TNF- a inhibitors ...between TNF- a ...first TNF-a inhibi- tor, a trend that was observed in our study as well, even when other biologic DMARDs were ...a TNF-a inhi- bitor, response ...
15
<p>ADAM17 Genetic Variants and the Response of TNF-α Inhibitor in Rheumatoid Arthritis Patients</p>
... 12. Iotchkova V, Huang J, Morris JA, et al. Discovery and re fi nement of genetic loci associated with cardiometabolic risk using dense imputa- tion maps. Nat Genet. 2016;48(11):1303 – 1312. doi:10.1038/ng.3668 13. ...
8
<p>Downregulation of MALAT1 alleviates saturated fatty acid-induced myocardial inflammatory injury via the miR-26a/HMGB1/TLR4/NF-κB axis</p>
... a TNF-α-induced apoptosis ...miR-26a inhibitor or miR-26 negative control (inhibitor NC) and TNF-α-specific siRNA (si-TNF-ɑ) were transfected in AC16 cells, followed by palmitic acid ...
11
PI3K/Akt inhibitor partly decreases TNF-α-induced activation of fibroblast-like synoviocytes in osteoarthritis
... with TNF-α and/or PI3K/ Akt inhibitor. For TNF-α treatment, each culture plate was treated by the recombinant human TNF-α (R&D Systems, Minneapolis, MN, USA) for 24 h at concentra- tions ...
13
Transiently lowering tumor necrosis factor-α synthesis ameliorates neuronal cell loss and cognitive impairments induced by minimal traumatic brain injury in mice
... weight TNF-α inhibitors in preclinical and clinical research, there is growing evidence that whereas physiological TNF-α levels are critical in normal brain physiology [37,38,55], excess TNF-α plays ...
14
Synthesis and biological evaluation of novel benzoxazole derivatives as potent TNF a and IL 6 inhibitor and antimicrobial agents
... cytokines TNF- α and IL-6 inhibition and antimicrobial activity (antibacterial and ...potent TNF- α and IL-6 inhibitor as compared to the standard dexamethasone but at the MIC of 10 µM, while the ...
5
Reversal of the Effects of TNF-alpha on In Vitro Derived Bovine Embryos by Addition of a Prostaglandin Synthesis Inhibitor, Indomethacin
... local, TNF-α will activate the expression of molecules within endothelial cells to trigger blood clotting to prevent the flow of the pathogen from entering the rest of the body via the blood ...of TNF-α ...
62